Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Revision label on the page updated from v3.6.5 to v3.6.6. This is a minor platform update and does not modify the study information shown.
    Difference
    0.1%
    Check dated 2026-08-29T23:55:54.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page’s revision tag has been updated to v3.6.5, indicating a minor update to the study record and page metadata. There are no apparent changes to substantive study information.
    Difference
    0.1%
    Check dated 2026-08-08T20:12:21.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The page version was updated from v3.6.3 to v3.6.4, indicating a minor site revision. There is no visible change to the study details or its presentation beyond the system version label.
    Difference
    0.1%
    Check dated 2026-07-25T11:45:20.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.6.2 to v3.6.3, indicating a minor update to the page. No substantive study content appears to be changed.
    Difference
    0.1%
    Check dated 2026-07-04T01:07:54.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.0 to v3.6.2, signaling a small maintenance update to the ClinicalTrials.gov study page rather than a substantive content change.
    Difference
    0.1%
    Check dated 2026-06-26T23:15:40.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    The page now presents new guidance/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and a 'No longer looking for participants' notice. The Intervention/Treatment heading has been updated and the older 'Intervention / Treatment' label removed, alongside a new revision indicator 'Revision: v3.6.0' replacing the previous version.
    Difference
    0.4%
    Check dated 2026-06-12T14:08:30.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.